INTRODUCTION {#S1}
============

T lymphocytes are integral players in the adaptive immune response. After development in the thymus, mature T cells recirculate between the blood, lymph and secondary lymphoid organs, where they scan antigen-presenting cells (APCs) for their cognate antigen^[@R1]^. The maintenance of the circulating naïve T cell population is the result of a balance between thymic output, survival, and homeostatic proliferation^[@R1],\ [@R2]^. Naïve T cell homeostasis is essential for maintaining the functional TCR repertoire necessary for ensuring immunity against foreign antigens while avoiding self-reactivity^[@R3],\ [@R4]^.

Nuclear pore complexes (NPCs) are aqueous channels that span the nuclear envelope^[@R5]^. Traditionally known as regulators of nucleocytoplasmic transport, it has become evident that they also play multiple transport-independent functions including the regulation of gene expression and chromatin organization^[@R6]^. NPCs are built from 32 different proteins known as nucleoporins^[@R5]^. While the structure of the NPC is conserved in all cells, the expression of several nucleoporins varies among different cell types and tissues, and mutations in various nucleoporins result in tissue-specific diseases^[@R7]^. This indicates that NPCs can be specialized to perform cell type-specific functions^[@R7]^. Supporting this idea, we recently identified that the tissue-specific nucleoporin Nup210^[@R8]^, is a critical regulator of skeletal muscle physiology^[@R9],\ [@R10]^. While Nup210 expression is absent in myoblasts, its incorporation into the NPCs of differentiating myotubes is both required and sufficient for myogenesis and myofiber maturation^[@R9],\ [@R10]^.

Here we identified that Nup210 deletion in mice specifically reduces the number of circulating naïve CD4^+^ T lymphocytes. We discovered that Nup210-deficient CD4^+^ T cells have reduced tonic TCR signaling, which compromises their survival in the periphery, and fail to properly activate in response to TCR ligation. We found that Nup210 mediates proximal TCR signaling by modulating the induction of the lipid raft protein Caveolin-2 (Cav2) following TCR activation. The findings that the *Cav2* gene is present at NPCs and that its efficient activation requires Nup210, support the emerging idea that NPCs act as scaffolds for the regulation of inducible genes^[@R10],\ [@R11],\ [@R12]^. We also identified that Nup210 is critical for the proper expression of cJun, which together with STAT3, prevents the expression of the Fas death receptor. Our findings reveal a cell intrinsic role for Nup210 in the regulation of CD4^+^ T cell homeostasis, and establish tissue-specific NPCs as key modulators of TCR signaling.

RESULTS {#S2}
=======

Nup210^−/−^ mice show reduced numbers of CD4^+^ T lymphocytes {#S3}
-------------------------------------------------------------

While analyzing *Nup210* mRNA levels in mouse adult tissues we found that this nucleoporin shows high expression levels in immune organs, including spleen, lymph nodes, and bone marrow ([Fig. 1a](#F1){ref-type="fig"}). Analysis of immune cell subsets revealed that T and B lymphocytes express higher levels of *Nup210* than eosinophils, macrophages, monocytes and neutrophils ([Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}). These results are consistent with publicly available ImmGen data^[@R13]^. To investigate the function of Nup210 in the immune system we generated a constitutive *Nup210* knockout mouse line (*Nup210*^−/−^) by deletion of exon 2, which completely abolishes expression of the protein ([Supplementary Fig. 1b, c](#SD2){ref-type="supplementary-material"}). *Nup210*^−/−^ mice are viable, fertile, have normal weight, and display no apparent phenotype. Consistent with our previous findings^[@R9]^, *Nup210*^−/−^ cells showed correct localization of nucleoporins ([Fig. 1b](#F1){ref-type="fig"}; [Supplementary Fig. 1d](#SD2){ref-type="supplementary-material"}), no nuclear envelope alterations or NPC clustering ([Fig. 1c](#F1){ref-type="fig"}), and normal nucleocytoplasmic transport ([Fig. 1d](#F1){ref-type="fig"}; [Supplementary Fig. 1e, f](#SD2){ref-type="supplementary-material"}), indicating no major defects in NPC assembly or function.

Analysis of blood and bone marrow in *Nup210*^−/−^ mice showed a significant decrease in the number of white blood cells (WBCs) specific to lymphocytes, with no detectable alterations in erythrocytes or myeloid cells ([Fig. 2a, b](#F2){ref-type="fig"}; [Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}). Detailed characterization of the lymphocyte populations in spleen revealed no changes in B cells or spleen cellularity ([Supplementary Fig. 2b, c](#SD2){ref-type="supplementary-material"}), but decreased proportion and number of CD3^+^ T lymphocytes ([Fig. 2c, d](#F2){ref-type="fig"}). Further analysis of the CD3^+^ population showed an abnormal CD4^+^/CD8^+^ T cell ratio (1.4 ± 0.05 in *Nup210*^+/+^ *vs.* 0.6 ± 0.02 in *Nup210*^−/−^; [Fig. 2e](#F2){ref-type="fig"}) that results from a strong reduction (\~60%) in the number of CD4^+^ T lymphocytes ([Fig. 2f, g](#F2){ref-type="fig"}). Importantly, we found no alterations in the number of CD8^+^ T cells, although their proportion within the CD3^+^ population was increased due to the reduced number of CD4^+^ T cells ([Fig. 2f, g](#F2){ref-type="fig"}). Within the CD4^+^ T cell population, we observed a decreased percentage of naïve cells and an increased percentage of the effector and central memory subsets ([Fig. 2h](#F2){ref-type="fig"}). This abnormal distribution results from a striking decrease (\>75%) in the number of naïve CD4^+^ T cells ([Fig. 2i](#F2){ref-type="fig"}). A similar decrease in naïve CD4^+^ T cells was observed in blood ([Supplementary Fig. 2d--f](#SD2){ref-type="supplementary-material"}). Numbers of TCRγδ T cells, natural killer (NK) cells, NKT cells, and regulatory T cells were not altered in *Nup210*^−/−^ mice ([Supplementary Fig. 2g--j](#SD2){ref-type="supplementary-material"}). These findings indicate that Nup210 is critical for the maintenance of the naïve CD4^+^ T cell population.

Nup210^−/−^ mice have normal T cell development and circulation {#S4}
---------------------------------------------------------------

To address whether the deficit in peripheral naïve CD4^+^ T lymphocytes is caused by abnormal T cell development, we analyzed T cell precursors in the thymus. We found no differences in the number or proportion of double negative (DN1--DN4) or double positive (DP) thymocyte populations between *Nup210*^+/+^ and *Nup210*^−/−^ mice ([Fig. 3a--d](#F3){ref-type="fig"}; [Supplementary Fig. 3a, b](#SD2){ref-type="supplementary-material"}). Furthermore, we observed equal numbers of single positive CD4^+^ and CD8^+^ T cells ([Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}) and confirmed that *Nup210*^−/−^ mice produce equal numbers of naïve CD4^+^ T cells as *Nup210*^+/+^ mice ([Supplementary Fig. 3d](#SD2){ref-type="supplementary-material"}). These findings indicate that T cells develop normally in *Nup210*^−/−^ mice, and suggest that the decrease in the naïve CD4^+^ T cells is caused by abnormalities in the periphery.

Once they exit the thymus, naïve T cells continuously recirculate between blood, lymph, and secondary lymphoid organs. The reduced number of CD4^+^ T cells in spleens and blood of *Nup210*^−/−^ mice could result from abnormal retention in lymph nodes, as shown for mice lacking the kinase TBK1^[@R14]^, or from the aberrant migration to non-lymphoid organs, as observed in the transcription factor *KLF2*^−/−^ mouse^[@R15]^. Analysis of peripheral and mesenteric lymph nodes showed the same decrease in naïve CD4^+^ T cells and no changes in the CD8^+^ T cell population ([Fig. 3e--h](#F3){ref-type="fig"}; [Supplementary Fig. 3e--g](#SD2){ref-type="supplementary-material"}), indicating that Nup210 deficiency does not cause T cell retention in secondary lymphoid organs. To determine whether naïve *Nup210*^−/−^ CD4^+^ T cells abnormally localize to non-lymphoid organs, RNA was isolated from tissues of *Nup210*^+/+^ and *Nup210*^−/−^ mice and the distribution of CD4^+^ T cells was analyzed by measuring *Cd4* mRNA levels^[@R15]^. Consistent with reduced numbers of CD4^+^ T cells in spleen and lymph nodes we observed decreased *CD4* expression in these tissues but no compensatory increases in any organ analyzed ([Fig. 3i](#F3){ref-type="fig"}). These results indicate that Nup210 depletion does not cause naïve CD4^+^ T cells to be abnormally retained in lymph nodes or mislocalized to non-lymphoid tissues.

Nup210 has a cell-intrinsic role in naïve CD4^+^ T cell survival {#S5}
----------------------------------------------------------------

The normal development and circulation of CD4^+^ T cells in *Nup210*^−/−^ mice suggests that the phenotype observed could result from survival defects in the periphery. To investigate this, T cells from *Nup210*^+/+^ and *Nup210*^−/−^ mice were isolated and labeled with the fluorescent tracking dyes CFSE and CTV, mixed at a 1:1 ratio and transferred into lymphoreplete recipient mice. Consistent with an intrinsic survival defect, the number of *Nup210*^−/−^ naïve CD4^+^ T cells recovered from spleens and lymph nodes seven days after co-transfer was significantly lower than control cells ([Fig. 4a](#F4){ref-type="fig"}; [Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}). Moreover, naïve CD4^+^ T cells isolated from *Nup210*^−/−^ mice exhibited increased expression of the pro-apoptotic factor Fas, increased staining with a cell death marker, and died faster than their wild-type counterparts when cultured ex vivo ([Fig. 4b--e](#F4){ref-type="fig"}; [Supplementary Fig. 4b](#SD2){ref-type="supplementary-material"}). Additionally, in a lymphopenia-induced proliferation (LIP) model where a mixture of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ T cells were adoptively transferred into sublethally irradiated wild-type hosts, *Nup210*^−/−^ T cells underwent less homeostatic proliferation, suggesting a reduced ability to sense survival signals ([Fig. 4f--h](#F4){ref-type="fig"}).

To further confirm that Nup210 has a cell-intrinsic function in CD4^+^ T cell survival we crossed mice in which exon 2 of *Nup210* is flanked by *lox*P sites (*Nup210*^f/f^) with *Cd4CreER^T2^* mice, to specifically delete Nup210 in CD4-expressing cells^[@R16]^. Consistent with our previous data, we observed a decrease in the CD4^+^ T cell population within 3 weeks of tamoxifen-induced Nup210 ablation ([Fig. 4i](#F4){ref-type="fig"}). These findings indicate that Nup210 expression is necessary for the survival and maintenance of peripheral naïve CD4^+^ T cells.

Nup210 is required for efficient TCR signaling {#S6}
----------------------------------------------

Naïve T cell homeostasis is largely maintained by two signals: the survival cytokine IL-7, and interactions of the T cell receptor (TCR) with self-peptides loaded on major histocompatibility complexes (self-pMHC), also known as tonic TCR signaling^[@R1],\ [@R2]^. These homeostatic signals are received locally in secondary lymphoid organs. Therefore the ability of naïve T cells to enter peripheral lymph nodes, known as homing, is essential for their survival^[@R1]^. We observed that *Nup210*^−/−^ naïve CD4^+^ T cells had a slight downregulation in the expression of CD62L ([Supplementary Fig. 5a](#SD2){ref-type="supplementary-material"}), a homing receptor required for this process^[@R17]^. To determine if *Nup210*^−/−^ naïve CD4^+^ T cells were able to migrate into peripheral lymph nodes, we adoptively transferred a mixture of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ T cells into wild-type recipient mice. Analysis of peripheral and mesenteric lymph nodes eighteen hours post-transfer showed equal recovery of *Nup210*^+/+^ and *Nup210*^−/−^ cells ([Fig. 5a](#F5){ref-type="fig"}; [Supplementary Fig. 5b](#SD2){ref-type="supplementary-material"}), indicating that naïve CD4^+^ T cells lacking Nup210 can efficiently home, and further confirming their ability to circulate normally.

These findings suggest that the survival defects of *Nup210*^−/−^ naïve CD4^+^ T cells might result from alterations in sensing survival signals in secondary lymphoid organs. Within lymph nodes, T cells encounter the survival cytokine IL-7, which upon binding to the IL-7 receptor (IL-7R) triggers STAT5 phosphorylation and promotes cell survival^[@R18]^. To determine whether Nup210 depletion affects IL-7 signaling, *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells were co-cultured in varying concentrations of IL-7 and STAT5 phosphorylation was measured. We observed no difference in the dose-dependent increase in p-STAT5 levels between *Nup210*^+/+^ and *Nup210*^−/−^ cells ([Fig. 5b, c](#F5){ref-type="fig"}), indicating that *Nup210*^−/−^ naïve CD4^+^ T cells can sense IL-7 efficiently.

The second survival signal received in lymph nodes results from TCR engagement with self-pMHC displayed on APCs. These interactions result in low levels of TCR signaling (tonic signaling), which are essential for naïve T cell survival^[@R19],\ [@R20],\ [@R21],\ [@R22]^. TCR stimulation initiates a signaling cascade that results in activation of the transcription factor NFAT and the up-regulation of AP-1 family members Jun and Fos^[@R23]^. Therefore, expression levels of AP-1 factors have long been used as a readout for TCR signaling^[@R24]^. Our whole-transcriptome sequencing (RNA-seq) analysis of unstimulated *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells (\>99% purity; [Supplementary Fig. 5c](#SD2){ref-type="supplementary-material"}) showed significantly reduced levels of members of the AP-1 family, being this pathway the most significantly altered in the dataset ([Fig. 5d--g](#F5){ref-type="fig"}; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Our analysis also showed significant alterations in the NFAT pathway (data not shown) and increased levels of apoptotic markers Fas and PUMA in *Nup210*^−/−^ naïve CD4^+^ T cells ([Fig. 5g](#F5){ref-type="fig"}), consistent with their decreased survival. The reduced levels of AP-1 factors JunB and cFos in unstimulated *Nup210*^−/−^ naïve CD4^+^ T lymphocytes were confirmed by real-time PCR and flow cytometric analysis ([Fig. 5h--j](#F5){ref-type="fig"}). These findings suggest that *Nup210*^−/−^ naïve CD4^+^ T cells have reduced basal TCR signaling. To confirm this, we isolated unstimulated *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells and determined the phosphorylation levels of downstream TCR effectors, including Lck; Zap70,; and PLC-γ1^[@R25]^. Because Lck is catalytically active when phosphorylated at the activating Tyr394 residue alone, or in combination with the inhibitory Tyr505 residue^[@R26]^, we analyzed the levels of both Lck modifications. As shown in [Figure 6a--e](#F6){ref-type="fig"} and [Supplementary Fig. 6a, b](#SD2){ref-type="supplementary-material"}, all these factors showed reduced phosphorylation levels in *Nup210*^−/−^ naïve CD4^+^ T cells at steady state, indicating that Nup210 depletion disrupts TCR signaling events. To further confirm that Nup210-deficient cells have defective basal TCR signaling naïve CD4^+^ T cells were stimulated with soluble anti-CD3 monoclonal antibody (mAb), which has previously been used to mimic *in vivo* tonic signaling^[@R27]^. We found that induction of the early TCR responsive gene Nur77^[@R28]^ was strongly impaired in *Nup210*^−/−^ CD4^+^ T cells ([Fig. 6f](#F6){ref-type="fig"}). Altogether, these observations indicate that Nup210 is required to sustain basal/tonic TCR signaling of naïve CD4^+^ T cells to promote survival.

Nup210 is required for CD4^+^ T lymphocyte activation {#S7}
-----------------------------------------------------

The discovery that Nup210 is required for proper tonic TCR signaling in naïve CD4^+^ T cells raised the question of whether this nucleoporin is also important for TCR-dependent activation. To investigate this, naïve populations of *Nup210*^+/+^ and *Nup210*^−/−^ CD4^+^ T cells were cultured in the presence of immobilized CD3 mAb plus costimulatory CD28 mAb, in the presence or absence of exogenous IL-2, and Nur77 protein levels were measured. In contrast to control cells, *Nup210*^−/−^ cells failed to increase Nur77 following TCR ligation regardless of IL-2 stimulation ([Fig. 6g, h](#F6){ref-type="fig"}). As previously reported, IL-2 addition did not alter Nur77 induction^[@R29],\ [@R30]^. We also detected a reduced frequency of *Nup210*^−/−^ naïve CD4^+^ T cells that upregulated the early activation marker CD69 relative to control cells ([Supplementary Fig. 6c, d](#SD2){ref-type="supplementary-material"}) and decreased cell division in response to TCR engagement ([Fig. 6i, j](#F6){ref-type="fig"}). Altogether, these findings indicate that the TCR signaling defect caused by Nup210 deficiency cannot be rescued by optimal activation conditions, and demonstrate that Nup210 is critical for proper TCR signaling during CD4^+^ T cell activation and proliferation.

Nup210 regulates early TCR signaling by promoting Caveolin-2 expression {#S8}
-----------------------------------------------------------------------

To dissect the molecular mechanism of Nup210 regulation TCR signaling and survival we knocked it out in human Jurkat J14 T cells expressing the TCR adaptor protein SLP-76 tagged with EYFP^[@R31]^ using CRISPR/Cas9. Single guide RNA oligonucleotides targeting exon 2 resulted in full depletion of Nup210 in these cells ([Fig. 7a, b](#F7){ref-type="fig"}). Analogous to the primary *Nup210*^−/−^ naïve CD4^+^ T cells, Nup210-depleted J14 cells showed lower levels of cFos in unstimulated conditions ([Fig. 7b](#F7){ref-type="fig"}), and reduced activation in response to CD3-induced TCR stimulation ([Fig. 7b, c](#F7){ref-type="fig"}; [Supplementary Fig. 7a](#SD2){ref-type="supplementary-material"}). Because TCR ligation leads to the rapid formation of SLP-76-containing TCR microclusters at the plasma membrane^[@R31],\ [@R32]^, clustering of SLP76-EYFP in these cells has been used as a reporter for proximal TCR activation^[@R31]^. Although it is unknown if clustering occurs during tonic TCR signaling *in vivo*, we found that stimulation with soluble anti-CD3 antibodies, which mimics tonic TCR signaling *in vitro*^[@R27]^, leads to SLP-76 clustering in J14 T cells ([Fig. 7d](#F7){ref-type="fig"}). Nup210 depletion in these cells completely abolished SLP-76 cluster formation in response to TCR activation ([Fig. 7d, e](#F7){ref-type="fig"}), confirming that Nup210 is critical for early TCR signaling and indicating a conserved role for Nup210 in TCR activation in humans.

The formation of clusters/signaling assemblies induced by TCR ligation is mediated by actin cytoskeletal rearrangements^[@R32]^, and the lipid raft protein Caveolin-1 (Cav1) has been shown to be required for this process^[@R33]^. The caveolin protein family includes two additional members, Cav2 and Cav3. While Cav3 is selectively expressed in muscle tissues^[@R34]^, Cav1 and Cav2 are more ubiquitous and can form hetero-oligomeric complexes^[@R35]^. Immunofluorescence analysis of Cav1 and Cav2 expression in J14 SLP-76-EYFP cells showed that both proteins were expressed at low levels, but only Cav2 was upregulated in response to TCR stimulation with soluble anti-CD3 antibodies ([Fig. 7f](#F7){ref-type="fig"}). Cav2 upregulation was not observed in Nup210-depleted cells, indicating a critical role for Nup210 in its induction ([Fig. 7f](#F7){ref-type="fig"}). Because Cav1 was found to be required for TCR signaling in CD8^+^ but not CD4^+^ T cells^[@R36]^, and J14 cells express the CD4 but not the CD8 coreceptor^[@R37]^, these findings raise the possibility that Cav2 is needed for TCR signaling specifically in CD4^+^ T cells. This would explain the CD4^+^ T cell-restricted phenotype of *Nup210*^−/−^ mice. To confirm that Nup210 modulates proximal TCR signaling through Cav2 we performed rescue experiments. For this, the ability of wild-type and Nup210-depleted J14 T cells transduced with control or Cav2-expressing lentiviruses to initiate TCR signaling was determined by analyzing SLP-76 clustering and Lck phosphorylation. Cav2 overexpression did not induce spontaneous activation or increased the activation of wild-type cells, but was sufficient to partially reestablish SLP-76 clustering upon TCR activation in Nup210-depleted cells ([Fig. 7g](#F7){ref-type="fig"}; [Supplementary Fig. 7b](#SD2){ref-type="supplementary-material"}). Ectopic Cav2 expression also restored Lck phosphorylation at the activating Tyr394 residue and promoted the dephosphorylation of the inhibitory Tyr505 ([Fig. 7h](#F7){ref-type="fig"}). These results confirm that Nup210 mediates proximal TCR signaling by promoting Cav2 expression. Interestingly, Cav2 was not able to rescue the TCR-induced increase in the expression of downstream genes ([Supplementary Fig. 7c](#SD2){ref-type="supplementary-material"}), indicating that Nup210 regulates TCR-induced gene expression through another mechanism.

The Cav2 gene localizes to the nuclear periphery {#S9}
------------------------------------------------

Our previous work identified that Nup210 regulates muscle physiology by modulating gene expression at the nuclear periphery^[@R10]^. To determine the intranuclear localization of the *Cav2* gene we performed fluorescence *in situ* hybridization (FISH) in primary naïve CD4^+^ T cells. We found that the *Cav2* gene, but not the *Nup62* gene whose expression is not regulated by Nup210, localizes to the nuclear periphery ([Fig. 8a, b](#F8){ref-type="fig"}). Recent work suggests that NPCs can act as scaffolds for regulation of inducible poised genes^[@R10],\ [@R11],\ [@R12]^. Interestingly, analysis of histone modifications from published data^[@R38],\ [@R39]^ shows that the *Cav2* promoter has active (H3K4me3) and repressive (H3K27me3) marks ([Supplementary Fig. 8b](#SD2){ref-type="supplementary-material"}). The presence of bivalent histone marks in a promoter is believed to maintain genes in a silent/low expression state while keeping them poised for rapid activation or stable silencing^[@R40]^. Notably, the *Cav1* gene, which is positioned next to the *Cav2* gene, only shows the repressive H3K27me3 mark ([Supplementary Fig. 8b](#SD2){ref-type="supplementary-material"}), indicating that localizing at the nuclear periphery is not sufficient to maintain a poised state. To determine if the *Cav2* gene at NPCs is poised for rapid activation in response to TCR stimulation we determined its kinetics of expression by analyzing the mRNA levels of *Cav1* and *Cav2* in primary naïve CD4^+^ T cells activated ex vivo. While no changes in *Cav1* expression were observed under these conditions, we found that *Cav2* expression was rapidly upregulated, with a kinetics similar to the early TCR-responsive gene *Irf4* ([Fig. 8c](#F8){ref-type="fig"}). Upregulation of *Cav2* was not observed in CD8^+^ T lymphocytes ([Supplementary Fig. 8c](#SD2){ref-type="supplementary-material"}), further supporting the idea that Cav2 function might be restricted to CD4^+^ T cells. Our results are consistent with earlier observations that *Cav1* and *Cav2* genes are independently regulated at the transcriptional level^[@R35]^, and indicate that in CD4^+^ T cells, the *Cav2* gene is set to be rapidly activated at the nuclear periphery in response to TCR stimulation in a Nup210-dependent manner.

Nup210 is required for the repression of the proapoptotic receptor Fas {#S10}
----------------------------------------------------------------------

Our RNA-seq analysis identified that AP-1 was the most significantly altered pathway in Nup210-deficient naïve CD4^+^ T cells ([Fig. 5e--j](#F5){ref-type="fig"}). FISH analyses in naïve CD4^+^ T lymphocytes showed that the *cJun* gene also localizes to NPCs ([Fig. 8b, d](#F8){ref-type="fig"}), suggesting that Nup210 might regulate its activity at the nuclear periphery. Previous studies found that cJun works with STAT3 to repress the expression of the cell death receptor *Fas*^[@R41]^. Because the association of STAT3 with the *Fas* promoter has depends on cJun^[@R41]^, and this AP-1 factor is strongly downregulated in Nup210-deficient cells, our findings suggest that in the absence of Nup210, recruitment of STAT3 to the *Fas* promoter might be impaired, resulting in de-repression of this gene. To test this, we analyzed the levels of STAT3 at the *Fas* gene promoter in wild-type and Nup210-depleted J14 cells using chromatin immunoprecipitation (ChIP). We found that *NUP210*^−/−^ cells exhibited a significant decrease in the recruitment of STAT3 to the *Fas* promoter ([Fig. 8e](#F8){ref-type="fig"}), even though the levels and localization of STAT3 were not affected ([Supplementary Fig. 8d, e](#SD2){ref-type="supplementary-material"}). These findings explain the higher levels of FasR in naïve CD4^+^ T lymphocytes of *Nup210*^−/−^ mice ([Fig. 4b, c](#F4){ref-type="fig"}; [Fig. 5f, g](#F5){ref-type="fig"}). To test if increased Fas levels render these cells more susceptible to cell death, we incubated *Nup210^+/+^* and *Nup210*^−/−^ naïve CD4^+^ T cells with Fas ligand (FasL), and measured cell survival. We found that *Nup210*^−/−^ cells showed increased cell death ([Fig. 8f](#F8){ref-type="fig"}). The same was observed using wild-type and Nup210-depleted J14 cells ([Supplementary Fig. 8f](#SD2){ref-type="supplementary-material"}). Altogether, our findings indicate that the death of peripheral naïve CD4^+^ T cells in *Nup210*^−/−^ mice results from a combination of their inability to sense survival tonic TCR signals and their increased sensitivity to Fas-mediated cell death ([Supplementary Fig. 8g](#SD2){ref-type="supplementary-material"}).

DISCUSSION {#S11}
==========

Accumulating evidence indicates the existence of specialized NPCs^[@R7]^, however the physiological functions of these structures remain largely unknown. Here, we discovered that deletion of the cell type-specific nucleoporin Nup210 in mice results in a dramatic reduction of circulating naïve CD4^+^ T cells. While the development and migration of these cells occurs normally, the survival of peripheral naïve CD4^+^ T lymphocytes in *Nup210*^−/−^ animals is compromised. The increased death of CD4^+^ T cells results from impaired tonic TCR signaling, which prevents the proper transmission of the survival signals provided by the TCR-self peptide/MHC interactions, and from increased levels of Fas, which sensitizes naïve CD4^+^ T lymphocytes to cell death. We found that Nup210 regulates these processes by modulating the expression of *Cav2* and *cJun* genes present at NPCs. While TCR stimulation-dependent upregulation of *Cav2* is critical for proximal TCR signaling, cJun expression is required for STAT3-dependent repression of Fas receptor. Our results uncover an unexpected role for Nup210 as a cell-intrinsic regulator of TCR signaling and T cell homeostasis; and expose NPCs as key players in the adaptive immune system.

Connections between NPCs and the immune system have recently emerged^[@R42],\ [@R43],\ [@R44],\ [@R45]^. Mice heterozygous for the nucleoporins Nup96 and Sec13 show reduced levels of MHC class I and class II in APCs^[@R43],\ [@R44]^. Decreased MHC expression in *Nup96*^+/−^ mice indirectly affects T cell expansion and the response to vesicular stomatitis virus infections^[@R43]^. Our findings that Nup210-deficient naïve CD4^+^ T cells show decreased survival and activation resulting from their inability to properly transmit TCR signals uncovered that NPCs also regulate T lymphocyte activity in a cell-intrinsic manner. Interestingly, the SLP-76 adaptor protein was recently found to interact with the NPC-associated protein RanGAP1 during T cell activation. This association was found to be required for the nuclear accumulation of NFAT and NF-κB^[@R42]^. This suggested that TCR activation can modulate the transport function of NPCs. Reciprocally, our findings indicate that NPCs modulate proximal and distal TCR signaling, allowing us to propose the existence of a positive regulatory loop between NPCs and TCRs that ensures the proper transmission of tonic and activation TCR signals.

Several reports have shown a critical role for Cav1 in the initiation and downstream TCR signaling cascade^[@R33],\ [@R36],\ [@R46]^. Cav1 was previously shown to be important for TCR signaling in CD8^+^, but not CD4^+^ T cells^[@R36]^. Here we report that TCR activation in naïve CD4^+^ T cells, but not in CD8^+^, results in the specific upregulation of Cav2. This selective, TCR activation-induced increase in Cav2 expression is required for proximal TCR signaling and is dependent on the expression of Nup210. These findings raise the possibility that Cav1 and Cav2 have specialized roles selectively regulating TCR signaling in different T lymphocyte subsets. In this context, the CD4^+^-specific upregulation of Cav2 and its dependence on Nup210 could explain why depletion of this nucleoporin affects only CD4^+^ T cell survival.

In muscle, Nup210 regulates genes that localize to NPCs by recruiting the transcription factor MEF2C^[@R10]^. The finding that the *Cav2* and *cJun* genes localize to the nuclear periphery indicates that the role of Nup210 in regulating NPC-associated genes is conserved in T cells. The identification that the nuclear periphery-associated *Cav2* gene is rapidly induced in response to TCR activation supports the idea that nuclear pores act as scaffolds for the regulation of inducible/poised genes^[@R10],\ [@R11],\ [@R12]^, and suggests that NPCs also act as a hub for the regulation of TCR signaling-related genes. What transcription factors regulate the activity of TCR signaling genes at the nuclear periphery is currently unknown, but it is worth noting that NFATc1, a central transcription factor of TCR signaling, was recently found to interact with Nup210 in T cells^[@R47]^. How Nup210, with its small NPC/nuclear-facing domain^[@R48]^, regulates gene expression is unclear. Most likely, and similar to its yeast counterpart Pom152, Nup210 interacts with other nuclear envelope^[@R49]^ components and other soluble factors to form a transcriptional regulatory complex at the nuclear periphery. It is also important to consider that Nup210 could be working outside NPCs. Lapetina *et al.* recently described novel non-NPC structures at the nuclear envelope of *Saccharomyces cerevisiae* that contain several nucleoporins and are involved in chromatin regulation^[@R50]^.

ON-LINE METHODS {#S12}
===============

Mice {#S13}
----

*Nup210*^flox/flox^ (*Nup210*^f/f^) mice were generated by nuclear injection of homologous DNA (The Center for Mouse Genome Modification (CMGM); University of Connecticut Health Center). To generate *Nup210*^−/−^ mice, *Nup210*^f/f^ mice were then crossed with *Hprt^Cre^* mice (Stock No. 004302, The Jackson Laboratory). A marker-assisted speed congenic breeding strategy was used to 99.9% backcross the mice to the C57BL/6J strain. To generate *Nup210*^f/f^-*Cd4CreER^T2^* mice, *Nup210*^f/f^ mice were crossed with *Cd4CreER^T2^* mice. *Cd4CreER^T2^* and TCRbeta- TCRdelta- (B6.129P2-*Tcrb^tm1Mom^ Tcrd^tm1Mom^*/J) mice were from The Jackson Laboratory (Stock No. 022356 and 002122). All animals were bred in specific-pathogen-free facilities at the Sanford Burnham Prebys Medical Discovery Institute (SBP). All experiments were approved by the Institutional Animal Care and Use Committee of SBP and were performed in accordance with institutional guidelines and regulations. Male and female mice were used at 6--10 weeks of age.

In vivo tamoxifen treatment {#S14}
---------------------------

*Nup210*^f/f^-*Cd4CreER^T2^* mice were administered 3 mg of tamoxifen (Sigma) suspended in corn oil intraperitoneally once daily for four days. Cre-induced Nup210 deletion was verified by PCR genotyping and immunofluorescence.

Cell culture {#S15}
------------

Mouse naïve CD4^+^ T cells (1.0 x 10^6^/ml) were cultured in RPMI-1640 medium containing 2.05 mM L-Glutamine and supplemented with 10% heat-inactivated FBS, 10 mM HEPES, 1% non-essential amino acids, 1 mM sodium pyruvate, penicillin-streptomycin, and 55 μM 2-mercaptoethanol. The J14 SLP-76-EYFP cell line was a kind gift of Dr. Lawrence E. Samelson (Laboratory of Cellular and Molecular Biology, NCI, NIH). J14 cells were maintained in RPMI-1640 medium containing 2.05 mM L-Glutamine and supplemented with 10% FBS, 2 mM GlutaMAX, and penicillin-streptomycin.

Viral transduction {#S16}
------------------

For CRISPR/Cas9 gene editing^[@R51]^ J14 SLP-76-EYFP cells transduced with tetracycline-inducible Cas9 lentivirus, followed by selection with 1.25 μg/ml Puromycin (Gibco). Cas9-expressing cells were then transfected with lentiviruses expressing scrambled or Nup210 CRISPR gRNAs^[@R52]^, and selected with 10 μg/ml Blasticidin (Gibco). Cas9 expression was induced with 2 μg/ml Doxycycline (Clontech) for three days. Doxycycline was removed from the medium and cells were single cell cloned. Clones depleted of Nup210 were identified by immunofluorescence. Two or more clones for each cell line were used for functional studies. For the Cav2 rescue studies, scramble or Nup210 knockout CRISPR cells were transduced with lentiviruses expressing human Cav2 (NM_001233.4) or empty vector and selected with 0.5 mg/ml Hygromycin (Gibco). Lentiviral vectors were produced by VectorBuilder.

Ex vivo and in vitro T cell activation {#S17}
--------------------------------------

Naïve CD4^+^ T cells were prepared from spleens and peripheral lymph nodes by negative selection. Cells were incubated with CD16/32 (93) and with biotin-labeled antibodies against B220 (RA3-6B2), CD11b (M1/70), CD11c (N418), CD19 (MB19-1), CD24 (M1/69), CD8 (53--6.7), CD25 (PC61), and CD44 (IM7), followed by immunomagnetic isolation using EasySep^TM^ Mouse Streptavidin RapidSpheres^TM^ Isolation Kit (STEMCELL Technologies). Efficacy of enrichment was analyzed by flow cytometry and the same number of viable, CD4^+^CD44^lo^CD25^−^ T cells were used per sample. Naïve CD8^+^ T cells were negatively isolated using the same methodology, except that a biotin-labeled CD4 antibody (RM4-5) was used instead of CD8. For TCR activation experiments, 0.2 x 10^6^ cells were cultured on 96-well plates at 1.0 x 10^6^/ml in T cell medium either with soluble or plate-bound anti-CD3 (1, 2 or 10 μg/ml; 145-2C11, LEAF^TM^ purified, BioLegend) alone or in combination with soluble anti-CD28 (5 μg/ml; 37.51, LEAF^TM^ purified, BioLegend), and recombinant murine IL-2 (20 ng/ml, PeproTech) for 14--16 hours at 37°C (for Nur77 analysis) or 48--72 hours (for proliferation analysis). For p-STAT5 activation, 0.2 x 10^6^ cells were cultured at 1.0 x 10^6^/ml in T cell medium supplemented with IL-7 (0.1 to 10 ng/ml; PeproTech) for 16 hours at 37°C. For J14 SLP-76-EYFP TCR activation, cells (1.0 x 10^6^/ml) were incubated in complete medium with or without 2% FBS and with 2 μg/ml soluble anti-CD3 antibody (OKT-3, BioXcell).

Fas-mediated apoptosis {#S18}
----------------------

Naïve CD4^+^ T cells (1.0 x 10^6^/ml) were co-cultured for 16--24 hours with splenocytes (4.0 x 10^6^/ml) from TCRbeta- TCRdelta- mice in medium supplemented with 0.1 μg/ml soluble Fas ligand (Enzo Life Sciences, Inc.), followed by flow cytometric analysis of cell viability using Annexin V (1/20 dilution in Annexin V binding buffer; BioLegend) or Propidium Iodide (10 μg/ml; Sigma). J14 SLP-76-EYFP cells were cultured for 16--24 hours in medium supplemented with 1% FBS and 0.01 or 0.1 μg/ml soluble Fas ligand (FasL).

Proliferation {#S19}
-------------

T cells (10--20 x 10^6^/ml) were labeled with 5 μM CFSE or CTV (Life Technologies) for 10 minutes at 37°C, washed with cold DMEM medium supplemented with 0.5% FBS and 10 mM HEPES, and cultured as described. Labeling efficiency was confirmed by flow cytometry and was \>99%. CFSE and CTV dilutions were analyzed 48 or 72 hours later for *in vitro* experiments, and 7 or 8 days later for in vivo experiments.

Adoptive transfer {#S20}
-----------------

T cells were isolated by negative enrichment, labeled with CFSE or CTV, and co-injected (normalized to 2 x 10^6^ CD4^+^CD44^lo^ cells of each) intravenously into wild-type mice. Spleen and lymph nodes were harvested 18 hours or 7 days later. For homeostatic proliferation, enriched T cells were labeled and co-injected (1 x 10^6^ T cells of each) into wild-type hosts sub-lethally irradiated using 600 Rad. CFSE and CTV dilutions were analyzed in spleens and peripheral lymph nodes 8 days later.

Blood composition analysis {#S21}
--------------------------

Blood was retro-orbitally collected in EDTA-coated tubes and analyzed by Vetscan HMII. For flow cytometric analysis, retro-orbital blood collection was performed using heparinized capillary tubes directly into 5 ml of red blood cell (RBC) lysis buffer (0.16 M Ammonium Chloride, 0.17 M Tris-HCl, pH 7.20). RBC lysis was performed for 1 hour at room temperature (RT). Samples were washed twice in HBSS containing 1% FBS, 0.5% HEPES, and penicillin-streptomycin and stained as indicated in the Flow Cytometry section.

Flow Cytometry {#S22}
--------------

Staining and washes were performed in 96-well plates. Unless otherwise stated, all incubations were performed in Staining Buffer (HBSS containing 1.2% FBS) for 30 minutes at 4°C. Primary antibodies were used at a final dilution of 1:100; except anti-Nur77, which was used at 1 μg per sample, and anti-p-STAT5, which was used at 0.06 μg per sample. Anti-Rabbit secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 647 (Life Technologies) were used at 1:1,000. For cell surface staining, freshly isolated cells (2 x 10^6^ cells per sample) were stained with LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies) or with Zombie NIR^TM^ Fixable Viability Kit (BioLegend) diluted at 1:500 in PBS at RT for 10 minutes, followed by incubation with fluorochrome-conjugated primary antibodies. For CCR7 surface staining, incubation was performed for 30 minutes at 37°C. Cells were either immediately analyzed by flow cytometry or fixed in 4% formaldehyde in PBS for later analysis. For intracellular staining of p-Lck, p-PLC-γ1, p-Zap70, and p-STAT5, after viability and surface staining, resting or IL-7 treated cells (0.2 x 10^6^ cells per sample) were fixed in 1.85% formaldehyde for 7 minutes at 37°C and post-fixed in 90% methanol for 30 minutes at 4°C. Cells were then stained with antibodies against p-Lck, p-PLC-γ1, p-Zap70, p-STAT5, or matching isotype control. A fluorescently conjugated secondary antibody was subsequently used. For intracellular staining of Nur77, JunB, and Foxp3, after viability and surface staining, resting or TCR-stimulated cells (0.2 x 10^6^ cells per sample) were fixed in BD Cytofix/Cytoperm (BD Biosciences) followed by post-fixation using the Foxp3/Transcription Factor Fixation/Permeabilization solution (eBioscience). Intracellular staining was performed with Nur77, JunB or Foxp3 antibodies diluted in Permeabilization Buffer (eBioscience). For JunB, a fluorescently conjugated secondary antibody diluted in Permeabilization Buffer was subsequently used. Flow cytometry data was acquired on a BD LSRFortessa^TM^ (BD Biosciences), or on a BD LSRFortessa^TM^ X-20 (BD Biosciences) using the BD FACSDIVA^TM^ Software (BD Biosciences); or on a ZE5^TM^ Cell Analyzer (Bio-Rad) using the Everest^TM^ software (Bio-Rad). Flow cytometry data were analyzed using FlowJo software v10.0.8r1 (Tree Star, Inc.).

Unless otherwise stated, all antibodies were purchased from BioLegend. Antibodies used: CD115 (AFS98); CD11b (M1/70); CD11c (N418); CD19 (MB19-1); CD24 (M1/69); CD16/32 Fc Block (93); CD197/CCR7 (4B12, eBioscience); CD25 (PC61); CD25 (3C7); CD3ε (145-2C11); CD3 (17A2, BD Biosciences); CD4 (GK1.5); CD4 (RM4-5); CD44 (IM7); CD45 (30-F11, eBioscience); CD45R/B220 (RA3-6B2); CD49b (DX5); CD62L (MEL-14); CD69 (H1.2F3, eBioscience); CD8a (53-6.7); cFos (9F6, Cell Signaling Technology); CD95 (Fas; Jo2, BD Biosciences); CD127 (A7R34); CD127 (SB/199, BD Biosciences); F4/80 (BM8); Foxp3 (FJK-16s, eBioscience); JunB (C37F9, Cell Signaling Technology); Ly-6C (AL-21, BD Biosciences); Ly-6G (1A8); NK1.1 (PK136); Nur77 (12.14, eBioscience); Siglec-F (E50-2440, BD Biosciences); Phospho-Lck (Tyr505) (Cell Signaling Technology); TCR β chain (H57-597); TCR γ/δ (GL3); Phospho-PLC-γ1 (Tyr783) (D6M9S, Cell Signaling Technology); Phospho-Zap70 (Tyr319)/Syk (Tyr352) (65E4, Cell Signaling Technology); and p-STAT5 (pY694) (47, BD Phosflow^™^; mouse IgG1 platelet control γ1 used as isotype control).

Fluorescence Activated Cell Sorting (FACS) {#S23}
------------------------------------------

Single cell suspensions were prepared from spleens and peripheral lymph nodes or bone marrow, and stained for flow cytometry as indicated in the flow cytometry section. Before sorting, cells were resuspended in FACS buffer (PBS containing 1% FBS). Live CD4^+^CD25^−^CD62L^hi^CD44^lo^ T cells were sorted at 4°C on a BD FACSAria I or II Cell Sorter (BD Biosciences) using a 70 μm nozzle into PBS supplemented with 2% FBS. Purity was verified after each sort and was \>99%. RiboLock RNase Inhibitor (10 U per sample; Thermo Fisher Scientific) was used for staining neutrophils (CD45^+^Ly-6G^+^CD11b^+^F4/80^−^), macrophages (CD45^+^F4/80^hi^CD11b^+^CD115^−^), monocytes (CD45^+^CD115^+^Ly-6G^−^Ly6C^+^CD11b^med^), eosinophils (CD45^+^Siglec-F^+^), CD4^+^ T cells (CD45^+^CD3^+^CD4^+^CD8^−^), CD8^+^ T cells (CD45^+^CD3^+^CD8^+^CD4^−^), and B cells (CD45^+^B220^+^CD3^−^) were sorted at 4°C on a BD FACSAria II Cell Sorter (BD Biosciences) using an 85 μm nozzle into Lysis Buffer (PureLink^TM^ RNA Micro Kit, Thermo Fisher Scientific). Bone marrow (BM) cells were flushed from tibia and femur using PBS containing 1.2% FBS and 5 mM EDTA.

RNA sequencing {#S24}
--------------

A total of three biological replicates of FACS-sorted cells were used, each consisting of cells pooled from 4 mice. RNA extraction was performed using the RNeasy Plus Micro Kit (QIAGEN) and RNA integrity was confirmed using the Agilent 2100 Bioanalyzer (Agilent Technologies). PolyA RNA was isolated using the NEBNext® Poly(A) mRNA Magnetic Isolation Module and barcoded libraries were made using the NEBNext® Ultra^™^ Directional RNA Library Prep Kit for Illumina® (NEB, Ipswich MA). Libraries were pooled and single end sequenced (1X75) on the Illumina NextSeq 500 using the High output V2 kit (Illumina Inc., San Diego CA). Read data was processed in BaseSpace (basespace.illumina.com). Reads were aligned to Mus musculus genome (mm10) using the BaseSpace RNA-Seq Alignment app v1.1 app and Tophat2 aligner (<http://tophat.cbcb.umd.edu/>) with default settings. Differential transcript expression was determined using the Cufflinks Cuffdiff package (<http://cufflinks.cbcb.umd.edu/>). Pathway analysis was performed using MetaCore^TM^ software (Thomson Reuters) and Ingenuity® Pathway Analysis (IPA®, QIAGEN). Hierarchical clustering of differentially expressed genes (q-value \< 0.05) in three *Nup210*^+/+^ and three *Nup210*^−/−^ naïve CD4^+^ T cell samples was performed on standardized data (gene expression rescaled for each sample to mean value of 0 and standard deviation of 1) in Partek Genomic Suite 6.6. Clustering was performed with average linkage algorithm and Euclidian distance as dissimilarity measure.

qPCR {#S25}
----

Total RNA extraction was performed from primary cells or homogenized tissues (QIAGEN TissueLyser LT, 5 cycles of 1 minute at 50 Hz) using the PureLink RNA Mini kit (Thermo Fisher Scientific), and up to 1 μg was used to synthesize cDNA using the QuantiTect Reverse Transcription Kit (QIAGEN). For the characterization of Nup210 expression in different tissues, commercial RNA (pooled from tissues of three 10-week old female or male mice; Zyagen) was used. qPCR was carried out using SYBR Green (BioRad or ThermoFisher Scientific) or TaqMan gene expression master mix (ThermoFisher Scientific). qPCR data were collected in a ABI 7900HT Real-Time PCR System (ThermoFisher Scientific) or in a CFX384 Real-Time PCR Detection System (Bio-Rad). The following primers were used to detect mouse transcripts. CD4: 5′-CCAACAGCGCCAGGCA-3′ and 5′-GCACTGGCAGGTCTTCTTCT-3′; Hprt^[@R53]^: 5′-TCATTATGCCGAGGATTTGGA-3′ and 5′-CAGAGGGCCACAATGTGATG-3′; GAPDH: 5′-CTTTGTCAAGCTCATTTCCTGG-3′ and 5′-TCTTGCTCAGTGTCCTTGC-3′ ; JunB: 5′-AGGCAGCTACTTTTCGGGTC-3′ and 5′-TTGCTGTTGGGGACGATCAA-3′; cFos: 5′-TTTCAACGCCGACTACGAGG-3′ and 5′-GCGCAAAAGTCCTGTGTGTT-3′ ; Cav1: 5′-ACGTAGACTCCGAGGGACA-3′ and 5′-GCGCGTCATACACTTGCTTC-3′ ; Cav2: 5′-TCAACTCTCATCTCAAGCTAGGC-3′ and 5′-AGGCAAGACCATTAGGCAGG-3′ ; and Irf4: 5′-GCTCATCACAGCTCATGTGGA-3′ and 5′-AACTCGTAGCCCCTCAGGAA-3′. The following primers were used to detect human transcripts. Egr2: 5′-ACGTCGGTGACCATCTTTCC-3′ and 5′-TTGATCATGCCATCTCCGGC-3′ ; cFos: 5′-GGAGAATCCGAAGGGAAAGGA-3′ and 5′-AGTTGGTCTGTCTCCGCTTG-3′ ; Hprt1: 5′-CCTGGCGTCGTGATTAGTGA-3′ and 5′-CGAGCAAGACGTTCAGTCCT-3′ ; Nfatc1: 5′-CAAGCCGAATTCTCTGGTGGT-3′ and 5′-ATGGCGTTACCGTTGGCG-3′ ; Il-2: 5′-CTGGAACTAAAGGGATCTGAAACA-3′ and 5′-AGTGTTGAGATGATGCTTTGACA-3′ ; Nur77: 5′-TACGAAACTTGGGGGAGTGC-3′ and 5′-CTGCACCCTACCCGGC-3′; and Cd69: 5′-GATGCCACCAGTCCCCATTT-3′ and 5′-TTGGCCCACTGATAAGGCAAT-3′. In addition, the following TaqMan® Gene Expression Assays (ThermoFisher Scientific) were used: Nup210 (Mm00497713_m1), β-actin (Mm00607939_s1), Gapdh (Mm99999915_g1), and Hprt (Mm00446968_m1).

Immunofluorescence and confocal microscopy {#S26}
------------------------------------------

Primary liver cells fixed in 4 methanol-free % PFA for 5 minutes were blocked and stained in IF buffer (1x PBS, 10 mg/ml BSA, 0.02% SDS, 0.1% Triton X-100). Primary and secondary antibodies was incubated for 1 hour at RT or overnight at 4°C with IF buffer washes between and after incubations. Cells were labeled with Hoechst 33342 (Life Technologies) for 5 minutes before mounting using VECTASHIELD (Vector Laboratories). Antibodies used: mAb414 (Covance or BioLegend); anti-Nup210 (Bethyl Laboratories, Inc.); anti-Pom121 (ThermoFisher Scientific); anti-Nup88 (22, BD Transduction Laboratories); anti-Nup107 (a kind gift from Martin Hetzer^[@R9]^, The Salk Institute, La Jolla CA, USA); anti-Nup98 (39A3, Cell Signaling Technology); anti-Nup93 (F2, Santa Cruz BioTechnology); anti-Lamin A (Sigma Aldrich); anti-Lamin B1 (Abcam); anti-Cav1 (Cell Signaling Technology), and anti-Cav2 (65, BD Biosciences). Images were taken using a Leica SP8 confocal microscope and analyzed using the Leica Application Suite X software v3.1.5.16308, ImageJ v2.0.0-rc-54/1.51h (NIH), and Adobe Photoshop CS5.1 v12.1 x64.

Fluorescence recovery after photobleaching (FRAP) {#S27}
-------------------------------------------------

Primary hepatocytes were isolated as described previously^[@R54]^. Cells were transfected with a plasmid expressing NES-Tomato-NLS^[@R9]^ using Lipofectamine 3000 (Life Technologies). 48 hours post-transfection, cells were imaged on a Leica SP8 confocal microscope. Nuclear tomato signal was photobleached with maximum laser power for 3 seconds. Recovery was recorded for 10 minutes and transport rates were analyzed using the LAS X software.

DNA fluorescence in situ hybridization (FISH) {#S28}
---------------------------------------------

Immunomagnetic isolated cells were spotted onto poly-L-lysine-coated coverslips and left to settle for 15--30 minutes at RT. Cells were then processed for immune-DNA FISH as described previously^[@R10]^, with the following modifications. Digoxigenin (DIG)-labeled probes were prepared by labeling 1 μg of BAC DNA using DIG-Nick Translation Mix (Sigma-Aldrich) and cells were subjected to IF with an anti-DIG antibody (Sigma-Aldrich). The following BAC probes from BACPAC resources, CHORI were used: Cav2 BAC (RP23-448I4), cJun BAC (RP24-282B18), and Nup62 BAC (RP23-403D23).

Electron microscopy {#S29}
-------------------

FACS-purified naïve CD4^+^ T cells were fixed in 2.5% glutaraldehyde with 2% paraformaldehyde in 0.15 M cacodylate buffer containing 2 mM calcium chloride, pH 7.4 for 18 hours at 4˚C. Cells were then embedded in 2% low melting point agarose (Sigma). The pellet was fixed in 1% osmium tetroxide/1.5% potassium ferrocyanide in buffer at 4˚C in the dark and then *en bloc* stained with 2% uranyl acetate at 4˚C in the dark, followed by a graded dehydration in acetone (50%, 70%, 90%, 100%, 100%). Samples were then rapidly infiltrated in Spurr's resin using a Ted Pella PELCO BioWave microwave processing unit, embedded in flat bottom tube, and cured at 60˚C overnight. 70 nm ultrathin sections were then cut on a Leica UC7 ultramicrotome and cells were examined on a Zeiss Libra 120kV PLUS Energy Filtered Transmission Electron Microscope at nominal magnifications of 8,000x and 16,000x.

Immunoblotting {#S30}
--------------

Immunoblotting was performed as described previously^[@R10]^, with the following modifications. Protein extracts were obtained using RIPA lysis buffer (tissues) or Tris-NP40 buffer (50mM Tris-HCL, 150mM NaCl, 0.5% NP-40, 1mM EDTA, 1mM MgCl~2~, 1mM DTT) (J14 cells) containing protease and phosphatase inhibitors (Pierce Halt Protease and Phosphatase Inhibitor Cocktail, ThermoFisher Scientific) and 1 mM PMSF (Sigma). Tissues were lysed using a QIAGEN TissueLyser LT (5 cycles of 30 seconds at 50 Hz). Protein concentration was determined using the Pierce BCA reagent (ThermoFisher Scientific). LDS Sample Buffer premixed with NuPAGE® Sample Reducing Agent (Life Technologies) was added, and samples were incubated for 10 minutes at 70°C. For western blot analysis, 100 μg of protein were resolved by SDS-PAGE on NuPAGE® Novex 3--8% Tris-Acetate or Bolt 4--12% Bis-Tris Plus protein gels (Life Technologies), and blotted to nitrocellulose membranes using an iBlot2. The following antibodies were used: anti-CD3ε (CD3-12, Cell Signaling Technology); anti-Nup210 (Bethyl Laboratories, Inc.; targets the C-terminal domain of Nup210, between residues 1837 and 1887); anti-Hsp90 (341320, R&D Systems); anti-cFos (9F6, Cell Signaling Technology); anti-Cav2 (65, BD Biosciences); anti-JunB (C37F9, Cell Signaling Technology); anti-Phospho-Lck (Tyr505) (Cell Signaling Technology); anti-Phospho-Lck (Tyr394) (755103, R&D Systems); anti-Lck (3A5, Santa Cruz BioTechnology); anti-human Lck (LCK-01, BioLegend); and anti-STAT3 (124H6, Cell Signaling Technology).

Chromatin Immunoprecipitation (ChIP) {#S31}
------------------------------------

Cells were diluted to 1 x 10^6^ cells/ml and incubated for 2 hours at 37°C in complete medium without FBS, in the presence (activated) or absence (control) of 2 μg/ml of anti-human CD3 antibody (OKT-3, BioXcell). ChIP assays were performed using the Zymo-Spin CHIP (Zymo Research) Kit with the following modifications. Cells were fixed in 1% formaldehyde (Sigma) for 10 min at RT followed by 5 min quenching with 125 mM glycine. Cells were then scraped, washed 3 times with ice-cold PBS, and centrifuged at 1,000 x G for 10 min. Cell pellets containing 1 x 10^7^ cells were resuspended in 500 μl lysis buffer with Protease Inhibitors and 1 mM PMSF. Chromatin shearing was performed with a Misonix S4000 Sonicator until DNA bands were between 300--500 bp. The chromatin solution was clarified by centrifugation and an aliquot of sheared chromatin was put aside for preparation of input sample. The remaining chromatin was immunoprecipitated using 10 μg of STAT3 (124H6, Cell Signaling Technology) or the mouse control IgG (Millipore) and Chip blocked Protein A/G magnetic beads (Millipore). Protein complexes were eluted and cross-links were reversed following the manufacturer's protocol. Immunoprecipitated DNA fragments were purified using spin columns and analyzed by qPCR using primers (5′-GAAGCCTTTAGAAAGGGCAGGA-3′, 5′-GGGAGGGCTCCATTGATTCAG-3′) designed to amplify a 189 bp fragment of the *Fas* core promoter previously described^[@R41]^.

Data analysis {#S32}
-------------

GraphPad Prism software v7.0a (GraphPad Software, Inc.) was used to prepare graphs and to perform statistical analysis. The scatter plot depicting the differentially expressed genes in *Nup210*^−/−^ naïve CD4^+^ T cells was prepared using R. ChIP-seq data for H3K4me3 and H3K27me3 in mouse naïve CD4^+^ T cells was accessed using the Cistrome Data Browser^[@R55]^ and visualized using the UCSC Genome Browser^[@R56]^.

Statistical analysis {#S33}
--------------------

Two-tailed unpaired Student's *t* test was used to compare outcomes (GraphPad Prism) and resulting *P*-values are indicated. For the RNA-seq samples, false discovery rate (FDR) adjusted *P*-values were calculated using the Benjamini-Hochberg correction for multiple testing with an allowed false discovery rate of 0.05 (Cufflinks).

Life Sciences Reporting Summary {#S34}
-------------------------------

Further information on experimental design is available in the Life Sciences Reporting Summary.

Data availability {#S35}
-----------------

The RNA-seq datasets generated during the current study are available in the NCBI biorepository at <https://www.ncbi.nlm.nih.gov/bioproject/438343>. The remaining data that support the findings of this study are available from the corresponding author upon request.

Supplementary Material {#S36}
======================

###### Supplementary Table 1

List of the differentially expressed genes in *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells. Flow cytometric-purified *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells were analyzed by RNA-seq. Data were collected from three independent experiments. A total of 3 biological replicates from each genotype, each prepared pooling cells from *n* = 4 mice per group, were sequenced. Differential transcript expression was determined using the Cufflinks Cuffdiff package (<http://cufflinks.cbcb.umd.edu/>). False discovery rate (FDR) adjusted *P*-values (*Q*-values) were calculated using the Benjamini-Hochberg correction for multiple testing with an allowed false discovery rate of 0.05. Further details can be found in the Methods section.
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![*Nup210*^−/−^ mice have normal NPC structure and functionality\
(**a**) qPCR analysis showing *Nup210* mRNA levels in mouse tissues. *Nup210* expression was normalized to *β-actin*, *Gapdh*, and *Hprt*. (**b**) Confocal microscopy showing nuclei isolated from *Nup210*^+/+^ or *Nup210*^−/−^ primary hepatocytes stained with the indicated antibodies and co-stained with Hoechst. mAb414: reacts with several FXFG repeat-containing nucleoporins, including Nup62, Nup153, Nup214, and Nup358/RanBP2. LmnA: Lamin A. Scale bar: 5 μm. (**c**) Immunoelectron micrographs of flow cytometrically-purified *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells. White arrowheads indicate NPCs. Images to the right show magnified NPCs. Scale bar: 0.5 μm. (**d**) Fluorescence recovery after photobleaching (FRAP) showing nuclear import of the NES-Tomato-NLS reporter in primary hepatocyte cells derived from *Nup210*^+/+^ and *Nup210*^−/−^ mice, as described^[@R9]^. The percentage of fluorescence recovery from photobleaching of the nucleus is shown. See [Supplementary Figures 1 e and f](#SD2){ref-type="supplementary-material"}. (**a**) Mean ± s.e.m, *n* = 3 mice per group, two independent experiments pooled; (**b**) representative of two independent experiments; (**c**) representative of two biological samples (male and female) for each genotype; samples were prepared pooling cells from *n* = 3 or 4 mice per group; (**d)** mean ± s.e.m, *n* = 7--9 cells per group, representative of two independent experiments.](nihms955745f1){#F1}

![Nup210 is required for naïve CD4^+^ T cell homeostasis\
Analysis of White Blood Cell (WBC) (**a**) and Red Blood Cell (RBC) (**b**) concentration in blood of *Nup210*^+/+^ and *Nup210*^−/−^ mice. Lym: lymphocytes; Mon: monocytes; Gra: granulocytes; HGB: Hemoglobin; HCT: Hematocrit; MCV: Mean Cell Volume; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular Hemoglobin Concentration; RDWc: Red Cell Distribution Width; PLT: Platelet; Pct: Platelet hematocrit; MPV: Mean Platelet Volume; PDWc: Platelet Distribution Width. (**c**--**i**) Flow cytometric analysis of *Nup210*^+/+^ and *Nup210*^−/−^ spleens. (c) Gating strategy used to define splenic CD3^+^ T cells. (d) Splenic CD3^+^ T cell numbers. (e) Splenic CD4^+^/CD8^+^ T cell ratios. (f) Gating strategy used to define splenic CD4^+^ and CD8^+^ T cell populations. (g) Splenic CD4^+^ and CD8^+^ T cell numbers. (h) Gating strategy used to identify naïve (CD62L^hi^CD44^lo^), effector memory (CD62L^lo^CD44^hi^) and central memory (CD62L^hi^CD44^hi^) splenic CD4^+^ T cells. (i) Splenic naïve and memory CD4^+^ T cell numbers. (**a**,**b**,**d**,**e**,**g**,**i**) mean ± s.e.m; each symbol represents an individual mouse; mice per group: (**a**,**b**) *n* = 4, (**d**) *n* = 28 or 29, (**e**) *n* = 35 or 39, (**g**) *n* = 37 or 41, and (**i**) *n* = 33 or 36. Data are representative of (**a**,**b**) two, (**c**) eight, (**f**) eleven, and (**h**) ten independent experiments, or are pooled from (**d**) eight, (**e**,**g**) eleven, and (**i**) ten independent experiments. NS, not significant (*P* \> 0.05); \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test).](nihms955745f2){#F2}

![*Nup210*^−/−^ mice have normal T cell development and circulation\
(**a**--**d**) Flow cytometric analysis of thymic populations of *Nup210*^+/+^ and *Nup210*^−/−^ mice. (a) Gating strategy used to subdivide double negative (DN) populations into DN1 (CD44^+^CD25^−^), DN2 (CD44^+^CD25^+^), DN3 (CD44^−^CD25^+^), and DN4 (CD44^−^CD25^−^). (b) Quantification of thymocyte populations from (a). (c) Gating strategy used to define single positive CD4^+^ and CD8^+^, double positive (DP), and DN thymocyte populations. (d) Quantification of thymocyte populations from (c). (**e**--**h**) Flow cytometric analysis of *Nup210*^+/+^ and *Nup210*^−/−^ mice peripheral lymph nodes (pLN: axillary, brachial and inguinal). (e) Total cell number. (f) CD4^+^/CD8^+^ T cell ratios. (g) CD4^+^ and CD8^+^ T cell number. (h) Number of naïve/memory CD4^+^ T cells. (**i**) *CD4* mRNA levels in different tissues from *Nup210*^+/+^ and *Nup210*^−/−^ mice were analyzed by qPCR. *CD4* expression was normalized to *Gapdh* and *Hprt*. (**b**,**d**--**h**) mean ± s.e.m, each symbol represents (**b**,**d**--**h**) an individual mouse, (**i**) mean ± s.d, each symbol represents a technical replicate; mice per group: (**b**) *n* = 8, (**d**) *n* = 14 or 15, (**e**) *n* = 19 or 24, (**f**) *n* = 26 or 28, (**g**) *n* = 19 or 22, (**h**) *n* = 15 or 17; (**i**) *n* = 3 technical replicates of one biological sample from each genotype, each prepared pooling cells from *n* = 2 mice per group. Data are representative of (**a**,**i**) two, (**c**) four independent experiments, or are pooled from (**b**) two, (**d**,**h**) four, (**e**,**g**) five, (**f**) nine independent experiments. NS, not significant (*P* \> 0.05); \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test).](nihms955745f3){#F3}

![Nup210 is required for peripheral naïve CD4^+^ T lymphocyte survival\
(**a**) Flow cytometry showing the number of naïve CD4^+^ (CD4^+^CD44^lo^) T cells recovered from spleens (Spl), peripheral (pLN) and mesenteric lymph nodes (mLN) 7 days after co-transfer of a 1:1 mixture of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ T cells into lymphoreplete *Nup210*^+/+^ hosts. Values were normalized to the ratio at time of transfer. (**b**,**c**) Flow cytometry showing Fas expression (b) and mean fluorescence intensity (MFI) (c) in resting naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells (FMO, fluorescence minus one). MFI is shown relative to that of *Nup210*^+/+^ mice. (**d**) Flow cytometry showing the percentage of dead naïve CD4^+^ (CD4^+^CD44^lo^) splenic T cells determined using a viability dye. (**e**) Flow cytometry showing the percentage of live naïve CD4^+^ (CD4^+^CD44^lo^) T cells over time in ex vivo cultured splenocytes. (**f**) Flow cytometry showing cell division of naïve CD4^+^ (CD4^+^CD44^lo^) T cells recovered from spleens and pLN 8 days after co-transfer of a 1:1 mixture of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ T cells into sublethally irradiated *Nup210*^+/+^ hosts. Cell proliferation was determined by dilution of the CFSE and CTV labels. The percentage of slow proliferating cells in each peak of division is indicated. (**g,h**) The percentage of cells from (g) that have divided 1--4+ times in spleens (g) and pLN (h) is shown. (**i**) Flow cytometry showing the percentage of circulating CD4^+^ T cells in *Nup210*^f/f^-*Cd4CreER^T2^* mice 3 weeks after CD4^+^ T cell-specific Nup210 depletion by tamoxifen treatment. (**a**,**c**--**e,g**--**i**) mean ± s.e.m; each symbol represents an individual mouse; mice per group: (**a**) *n* = 4, (**c**) *n* = 5, (**d**) *n* = 12 or 13, (**e**) *n* = 7 or 8, (**g**,**h**) *n* = 6, (**i**) *n* = 4 or 5. Data are representative of (**a**,**i**) two, (**b**,**c,f**--**h**) three independent experiments, or are pooled from (**d**) five, (**e**) two independent experiments. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test).](nihms955745f4){#F4}

![*Nup210*^−/−^ naïve CD4^+^ T cells show features of altered TCR signaling\
(**a**) Flow cytometry showing the number of naïve CD4^+^ (CD4^+^CD44^lo^) T cells recovered from peripheral (pLN) and mesenteric lymph nodes (mLN) 18 hours after co-transfer of a 1:1 mixture of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ T cells into lymphoreplete *Nup210*^+/+^ hosts. Values were normalized to the ratio at time of transfer. (**b**) Flow cytometric analysis of STAT5 (pY694) expression in unstimulated (dashed lines) or IL-7-treated (solid lines) CD4^+^CD44^lo^ T cells. (**c**) Mean fluorescence intensity (MFI) from (b) is shown relative to that of *Nup210*^+/+^ mice. (**d**--**g**) RNA-seq analysis of flow cytometric-purified *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells. (d) Scatter plot depicting the differentially expressed genes (DEG) in *Nup210*^−/−^ cells. Genes were organized by log~2~ (fold change) and -log~10~ (q-value). Genes below the cutoff (dashed line: q-value of 0.05) are shown in gray. Downregulated genes are shown in blue, and upregulated genes are shown in red. (e) The most significantly altered pathways from (d) ranked by p-value are shown. The AP-1 pathway is highlighted in red. (f) Hierarchical clustering of DEG (q-value \< 0.05). Each sample (\#1--3) is a pool of 4 mice. AP-1 pathway members are depicted. Red and blue colors show upregulated and downregulated genes, respectively. (g) Heatmap illustrating the log~2~ (fold change) values of selected genes in *Nup210*^−/−^ relative to *Nup210*^+/+^ animals. (**h**) qPCR analysis of *JunB* and *cFos* expression in naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells normalized to *Hprt*. (**i**,**j**) Flow cytometric analysis of JunB expression (i) and MFI (j) in unstimulated CD4^+^CD62L^hi^CD44^lo^CD25^−^Foxp3^−^ T cells. Secondary Ab: fluorescently labeled secondary antibody stained sample. MFI values are shown as a percentage of *Nup210*^+/+^ cells. (**a**,**h**,**j)** mean ± s.e.m. (**c**) mean ± s.d; each symbol represents (**a**,**j**) an individual mouse or (**c**) a technical replicate or (**h**) a biological sample; (**a**) *n* = 3 or 4 host mice, (**c**) *n* = 3 technical replicates of one biological sample from each genotype, each prepared pooling cells from *n* = 2 or 3 mice per group, (**h**) *n* = 3 biological samples from each genotype, each prepared pooling cells from *n* = 4 mice per group, (**j**) *n* = 4 or 5 mice per group. Data are representative of (**a**--**c**,**j**) two, (**d**--**g**) three independent experiments, or are pooled from (**h**,**i**) three independent experiments. (**d**--**g**) false discovery rate (FDR) adjusted *P*-values were calculated using the Benjamini-Hochberg correction for multiple testing with an allowed false discovery rate of 0.05. NS, not significant (*P* \> 0.05); \**P* ≤ 0.05, \*\**P* ≤ 0.01 (two-tailed unpaired Student's *t*-test).](nihms955745f5){#F5}

![Nup210 is required for TCR signaling\
(**a**) Immunoblot analysis of p-Lck (Y394) and total Lck protein levels in *Nup210*^+/+^ and *Nup210*^−/−^ naïve CD4^+^ T cells. Hsp90 used as loading control. (**b**,**c**) Flow cytometric analysis of p-Lck (Y505) expression (b) and mean fluorescence intensity (MFI) (c) in resting naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells from *Nup210*^+/+^ and *Nup210*^−/−^ mice. Activation with sodium peroxyvanadate used as positive control. Secondary Ab: fluorescently labeled secondary antibody stained sample. MFI is shown relative to that of *Nup210*^+/+^ mice. (**d**,**e**) Flow cytometric analysis of p-PLC-γ1 (Y783) expression (d) and MFI (e) in resting naïve CD4^+^ (CD4^+^CD62L^hi^CD44^lo^CD25^−^) T cells from *Nup210*^+/+^ and *Nup210*^−/−^ mice. (**f**) Flow cytometric analysis of Nur77 expression in *Nup210*^+/+^ or *Nup210*^−/−^ CD4^+^CD44^lo^ T cells stimulated for 16 hours with soluble (sol.) anti-CD3 mAb. Values are displayed relative to sol. anti-CD3-stimulated *Nup210*^+/+^ cells. (**g**) Flow cytometric analysis of Nur77 expression in unstimulated (left) or TCR-stimulated (right) *Nup210*^+/+^ and *Nup210*^−/−^ CD4^+^CD44^lo^ T cells. TCR stimulation was performed with plate-bound anti-CD3 and anti-CD28 mAbs, and soluble IL-2 for 14 hours. FMO, fluorescence minus one. (**h**) Flow cytometric analysis of Nur77 levels in CD4^+^ T cells stimulated as in (g) or without IL-2 supplementation. Values shown are relative to control treated cells. (**i**) Flow cytometric analysis of CFSE and CTV dilutions 48 hours after stimulation of CFSE-labeled *Nup210*^+/+^ and CTV-labeled *Nup210*^−/−^ CD4^+^CD44^lo^ T cells with plate-bound anti-CD3/ anti-CD28 mAbs and soluble IL-2. The percentage of cells that have undergone proliferation is indicated. (**j**) The percentage of cells from (i) that underwent 1--3 divisions was quantified. (**c**,**e**,**h**) mean ± s.e.m., each symbol represents an individual mouse, (**f**,**j**) mean ± s.d.; each symbol represents a technical replicate; (**a**) biological samples prepared pooling cells from n = 4 or 8 mice; mice per group: (**c**) *n* = 8 or 9, (**e**) *n* = 13 or 14, (**h**) *n* = 4 or 5; (**f**) *n* = 2 technical replicates of one biological sample from each genotype, each prepared pooling cells from 4 mice; (**j**) *n* = 3 technical replicates of one biological sample from each genotype, each prepared pooling cells from 5 or 10 mice per group. Data are representative of (**a**,**f**,**i**,**j**) two, (**b**,**d**,**g**,**h**) three independent experiments, or are pooled from (**c**,**e**) three independent experiments. NS, not significant (*P* \> 0.05); \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test).](nihms955745f6){#F6}

![Nup210 is required for the TCR-dependent induction of Cav2 expression\
(**a**) Immunofluorescence analysis of Nup210 and mAb414 in *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. (**b**) Immunoblot analysis of Nup210 and cFos in resting and soluble anti-CD3-activated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. Hsp90 was used as loading control (\>exp: higher exposure). (**c**) qPCR analysis of *Il2* mRNA levels in resting or soluble anti-CD3-activated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. *Il2* expression was normalized to *Hprt1*. (**d**) Immunofluorescence analysis of SLP-76 clustering on the surface of unstimulated or anti-CD3-activated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. (**e**) The percentage of cells with SLP-76 foci from (d) was quantified. (**f**) Immunofluorescence analysis of Cav1 and Cav2 in unstimulated or anti-CD3-activated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. (**g**) The percentage of activated (SLP-76 cluster-positive cells) *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells expressing control (empty vector) or Cav2 was quantified after stimulation with soluble anti-CD3. (**h**) Immunoblot analysis of Nup210, Cav2, p-Lck Y394, p-Lck Y505, and total Lck in unstimulated or anti-CD3-activated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells expressing control or Cav2. Hsp90 was used as loading control. (**a**,**b**,**d,f**) representative of three independent experiments; (**c**) mean ± s.d., each symbol represents a technical replicate *n* = 3, representative of three independent experiments; (**e**,**g**) mean ± s.e.m, pooled from four independent experiments, *n* = 4 biological samples, *n* ≥ 200 cells per group; (**h**) representative of two independent experiments. NS, not significant (*P* \> 0.05); \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test). Scale bar: 5 μm.](nihms955745f7){#F7}

![*Cav2* and *cJun* genes localize to the nuclear periphery and Nup210 is required for the repression of the proapoptoticreceptor Fas\
(**a**) DNA-FISH analysis of *Cav2* and *Nup62* in *Nup210*^+/+^ naïve CD4^+^ T cells. Gene loci are shown in red and the nuclear periphery marker Lamin B1 in green. (**b**) The percentage of nuclei from (a) that show one or both loci associated with the nuclear periphery was quantified from 3D nuclear reconstructions (see [Supplementary Fig. 8a](#SD2){ref-type="supplementary-material"}). (**c**) qPCR analysis of *Cav1*, *Cav2*, and *Irf4* mRNA levels in *Nup210*^+/+^ naïve CD4^+^ T cells unstimulated or activated with soluble anti-CD3. Expression was normalized to *Hprt*. (**d**) DNA-FISH of *cJun* in *Nup210*^+/+^ naïve CD4^+^ T cells. Gene loci (red) and Lamin B1 (green). (**e**) Chromatin immunoprecipitation (ChIP) analysis of STAT3 binding to the *Fas* promoter in unstimulated *NUP210*^+/+^ or *NUP210*^−/−^ J14 SLP-76-EYFP cells. Binding of STAT3 was quantified by qPCR. (**f**) Flow cytometric viability analysis of *Nup210*^+/+^ or *Nup210*^−/−^ naïve CD4^+^ T cells co-cultured with splenocytes from TCRbeta- TCRdelta- mice and soluble FasL. Viability was determined using annexin V and propidium iodide staining. (**a**,**d**) representative of three independent experiments; (**b**) mean ± s.d. pooled from three independent experiments, *n* ≥ 200 cells quantified from *n* = 4, 5 or 8 individual fields, symbols show individual field quantification; (**c**) mean ± s.e.m, *n* = 5 mice per time point, representative of one experiment; (**e**) mean ± s.d., each symbol represents a technical replicate, *n* = 3, representative of two independent experiments, (**f**) mean ± s.e.m, each symbol represents an individual mouse, *n* = 9 mice per group, data pooled from two independent experiments. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001, \*\*\*\**P* ≤ 0.0001 (two-tailed unpaired Student's *t*-test). Scale bar: 5 μm.](nihms955745f8){#F8}
